secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-09-08T13:00:42+00:00
Accession:  0001493152-26-041716
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics signs exclusive distribution deal with Akron Biotech for HCW11-006 reagent
--------------------------------------------------------------------------------

- Exclusive worldwide distribution (ex-China) of HCW11-006 as CAR-T manufacturing reagent; 5-year term.
- Advance payments: $200k at closing, $100k within 30 days of Supply Agreement, $100k on each of 1st and 2nd anniversaries.
- Closing by Nov 30, 2026, subject to due diligence and product testing; Supply Agreement to be negotiated within 60 days of closing.
- HCW11-006 is a multi-cytokine fusion molecule; preclinical data show CAR-Ts made with it have enhanced anti-tumor and antiviral activity.
- Akron is a leading supplier of ancillary materials for cell/gene therapy; deal marks first commercialization of HCW's TRBC platform product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226041716/0001493152-26-041716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226041716/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-041716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer